

产品名称: CK-636

产品别名: CK-636

生物活性:																									
Description	CK-636 is a cell permeable inhibitor of Arp2/3 complex, that could inhibit actin polymerization, with IC ₅₀ values of 4 μM, 24 μM and 32 μM for human, fission yeast and bovine, respectively.																								
IC ₅₀ & Target	IC50: 4/24/32 μM (Human/fission yeast/bovine Arp2/3)[1].																								
In Vitro	CK-636 binds between Arp2 and Arp3, where it appears to block movement of Arp2 and Arp3 into their active conformation. CK-636 inserts into the hydrophobic core of Arp3 and alters its conformation. CK-636 prevents actin polymerization and the formation of actin filament comet tails by Listeria in infected SKOV3 cells (IC ₅₀ =22 μM)[1]. Additionally, CK-636-treated T cells exhibits elongated morphology with sharp pseudopodia at the leading edges, while the breadth of the CK-636-treated T cells is about 30% less than that of DMSO-treated T cells[2].																								
Solvent&Solubility	<p>In Vitro:</p> <p>DMSO : ≥ 49 mg/mL (172.30 mM)</p> <p>H₂O : < 0.1 mg/mL (insoluble)</p> <p>* "≥" means soluble, but saturation unknown.</p> <table border="1"><thead><tr><th rowspan="2">Preparing Stock Solutions</th><th>Solvent / Mass</th><th>1 mg</th><th>5 mg</th><th>10 mg</th></tr><tr><th>Concentration</th><th></th><th></th><th></th></tr></thead><tbody><tr><td>1 mM</td><td>3.5164 mL</td><td>17.5821 mL</td><td>35.1642 mL</td></tr><tr><td>5 mM</td><td>0.7033 mL</td><td>3.5164 mL</td><td>7.0328 mL</td></tr><tr><td>10 mM</td><td>0.3516 mL</td><td>1.7582 mL</td><td>3.5164 mL</td></tr></tbody></table> <p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。 -80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。</p> <p>In Vivo:</p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液, 再依次添加助溶剂:</p> <p>——为保证实验结果的可靠性, 澄清的储备液可以根据储存条件, 适当保存; 体内实验的工作液, 建议您现用现配, 当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶</p> <p>1.请依序添加每种溶剂: 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution 此方案可获得 ≥ 2.5 mg/mL (8.79 mM, 饱和度未知) 的澄清溶液。 以 1 mL 工作液为例, 取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中, 混合均匀。向上述体系中加入 50 μL Tween-80, 混合均匀; 然后继续加入 450 μL 生理盐水定容至 1 mL。</p> <p>2.请依序添加每种溶剂: 10% DMSO→ 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (8.79 mM); Suspended solution; Need ultrasonic 此方案可获得 2.5 mg/mL (8.79 mM)的均匀悬浊液, 悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例, 取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中, 混合均匀。</p>				Preparing Stock Solutions	Solvent / Mass	1 mg	5 mg	10 mg	Concentration				1 mM	3.5164 mL	17.5821 mL	35.1642 mL	5 mM	0.7033 mL	3.5164 mL	7.0328 mL	10 mM	0.3516 mL	1.7582 mL	3.5164 mL
Preparing Stock Solutions	Solvent / Mass	1 mg	5 mg	10 mg																					
	Concentration																								
1 mM	3.5164 mL	17.5821 mL	35.1642 mL																						
5 mM	0.7033 mL	3.5164 mL	7.0328 mL																						
10 mM	0.3516 mL	1.7582 mL	3.5164 mL																						

	<p>3.请依序添加每种溶剂： 10% DMSO → 90% corn oil Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution</p> <p>此方案可获得 ≥ 2.5 mg/mL (8.79 mM, 饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中，混合均匀。</p>
References	<p>[1]. Nolen BJ, et al. Characterization of two classes of small molecule inhibitors of Arp2/3 complex. <i>Nature</i>. 2009 Aug 20;460(7258):1031-4.</p> <p>[2]. Kwon KW, et al. Migration of T cells on surfaces containing complex nanotopography. <i>PLoS One</i>. 2013 Sep 12;8(9):e73960.</p>



源叶生物